ROCKLAND, Mass.--(BUSINESS WIRE)--July 27, 2006--BioSphere Medical, Inc. (NASDAQ: BSMD - News), a medical device company that has pioneered the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations, today reported that total revenues for the second quarter of 2006 were a record $5.64 million, compared with total revenues of $4.49 million for the second quarter of 2005, an increase of 26%. In the second quarter of 2006, revenues in the United States were $4.14 million, compared to revenues of $2.99 million in the second quarter of 2005, an increase of 39%. Revenues outside of the United States were $1.50 million for the second quarter of 2006, unchanged from the same period in 2005. Global sales of Embosphere® Microspheres were $4.82 million in the second quarter of 2006, compared to $3.72 million in the second quarter of 2005, an increase of 30%. Sequential revenue growth for the second quarter of 2006 as compared to the first quarter of 2006 was 7% for total sales, and 14% for United States sales.
